Journal Watch · Frontiers in Immunology · 2026
Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study.
These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
TL;DR
These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
Key findings
- At baseline and at each follow-up time point, the clinical results were evaluated by disease-specific grading scale, and the correlations between biomarker spectrum and disease activity was explored.<h4>Results</h4>A total of 60 patients were enrolled, with 27, 19, and 14 patients assigned to the rituximab, ripertamab, and efgartigimod groups, At the 3-month post-treatment assessment, the mean of the INCAT score decreased by 0.519 points in the rituximab group, 1.737 points in the ripertamab group, and 0.214 points in the efgartigimod group as compared to baseline.<h4>Conclusion</h4>Ripertamab demonstrated efficacy in managing short-term disease outcomes in patients with CIDP, with no significant difference observed when compared to rituximab or efgartigimod.
- These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
What they did
A total of 60 patients were included.
Full abstract (original)
Background: <h4>Objective</h4>To analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical outcomes, and biomarker characteristics.<h4>Methods</h4>A multicenter, retrospective cohort study was conducted, patients diagnosed with CIDP were enrolled if they had received at least one course of ripertamab, rituximab, or efgartigimod.
What they did: A total of 60 patients were included.
Results & conclusions: At baseline and at each follow-up time point, the clinical results were evaluated by disease-specific grading scale, and the correlations between biomarker spectrum and disease activity was explored.<h4>Results</h4>A total of 60 patients were enrolled, with 27, 19, and 14 patients assigned to the rituximab, ripertamab, and efgartigimod groups, At the 3-month post-treatment assessment, the mean of the INCAT score decreased by 0.519 points in the rituximab group, 1.737 points in the ripertamab group, and 0.214 points in the efgartigimod group as compared to baseline.<h4>Conclusion</h4>Ripertamab demonstrated efficacy in managing short-term disease outcomes in patients with CIDP, with no significant difference observed when compared to rituximab or efgartigimod. These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1825584 · PubMed 42238571.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. A total of 60 patients were included.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1825584. PubMed ID: 42238571. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/comparative-efficacy-of-ripertamab-rituximab-and-efgartigimod-in-chronic-825584/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides